#VPAS

Will ABPI’s ambitious VPAG plans succeed VPAS?

Discussions are beginning on the next iteration of the UK’s voluntary scheme for branded medicines, pricing and access (VPAS) and the Association of the British Pharmaceutical Industry (ABPI) has set out its stall to government. It has published a four-point proposal for a Voluntary Scheme for Pricing, Access and Growth (VPAG), designed to reignite competitiveness and boost innovation in the life sciences sector, thereby improving health outcomes and the wider economy.

15 May 2023

The 2023 ABPI annual conference focused on growing the Life Sciences

The 2023 annual conference of the UK’s Association of the British Pharmaceutical Industry (ABPI) at the end of April had a theme of Growing the UK as a Global Hub for Life Sciences.

9 May 2023

Government confirms increase to pharma’s statutory scheme

Despite opposition from the Association of the British Pharmaceutical Industry (ABPI), the UK government has confirmed its plans to raise the revenue clawback rate paid by pharma for branded medicines under the statutory scheme by just over 3%, from 24.4% to 27.5% for 2023.

9 Mar 2023

ABPI asks UK government to review VPAS as clawback will hit 26.5% of sales revenue in 2023

In 2023 manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government under the 2019 Voluntary scheme for branded medicines, pricing and access (VPAS), according to the Association of the British Pharmaceutical Industry (ABPI).

20 Dec 2022

Will ABPI’s ambitious VPAG plans succeed VPAS?

The 2023 ABPI annual conference focused on growing the Life Sciences

Government confirms increase to pharma’s statutory scheme

ABPI asks UK government to review VPAS as clawback will hit 26.5% of sales revenue in 2023

Categories

Tags